A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients N Pfeiffer, R Hennekes, E A Lippa, F Grehn, H Garus, F L Brunner-Ferber Abstract MK-927 is a novel topical carbonic anhydrase inhibitor (CAI). We present the first singledose clinical trial ofMK-927 in 24 If patients were considered eligible all previous hypotensive therapy was discontinued for a minimum of 72 hours for parasympathomimetics and 14 days for all other ocular hypotensive medications. After that washout period the patients returned to the clinic, and a prestudy diurnal IOP curve was performed with IOPs measured bilaterally at 1000, 1100, 1200, 1300, 1430, 1600, and 1800 hours. To be admitted into the study, the IOP at 1000 had to be ¢24 mmHg in each eye, with a difference between eyes of s:6 mmHg. (Table II) . The mean differences between eyes did not exceed 0-8 mmHg at any time point. As expected, diurnal variation occurred, with the IOP being lower in the afternoon (Fig 2) .
MK-
On the treatment day the eyes treated with MK-927 showed a sustained decrease of IOP throughout the diurnal curve, with a peak mean change from predose pressure of -10-5 mmHg (peak mean percentage change -33 1%) at 4-5 hours after treatment (Table III) . At eight hours after treatment the mean IOP of MK treated eyes had not returned to prestudy day levels. In contrast, placebo treated eyes showed a peak mean change of -5-1 mmHg (-16-6%) at 4-5 hours. At 8 hours the mean IOP had returned to prestudy day levels (Fig 2) . When comparing prestudy and treatment-day diurnal curves we noted a significant difference in the mean IOP of the MK-927 treated eyes at all time points after treatment (Table II) . In contrast, for the contralateral eyes we noted a significant difference between IOP on prestudy and treatment day only at 1 hour after treatment. The mean decrease in IOP in MK-927 treated eyes on the treatment day was significantly greater than the mean decrease on the prestudy day at each point after treatment, p<0-01 (Table III) .
To compensate for diurnal variation in the IOP we calculated the net change in IOP (AA-IOP) at each time point on the treatment day. For each time point this was defined as the change in IOP from immediately before treatment (1000) on the treatment day minus the corresponding change in IOP from 1000 on the prestudy diurnal curve day. MK (parallel time prestudy day) peak mean AA-IOP for placebo treats -1-4 mmHg and occurred at 1 I treatment (Fig 3) . At each time poin AA-IOP was significantly greater fo treated eyes than for placebo tre (p<O'Ol).
Pressure reduction was not analysed to iris colour since the distribution v (17 blue, three hazel, two green, two l
The patients were monitored for effects. Four patients reported bilater of vision and one patient bilateral foi sensation at 10 minutes after treaty patient had burning at 10 min in th treated eye. Visual acuity remained in most patients and dropped one to th five MK-927 treated eyes and in s treated eyes, usually at 10 min after Mild bilateral corneal punctate eror seen towards the end ofthe day in 16 p, were considered to be induced b) applanation tonometry. One patient h9 conjunctival hyperaemia. No syst effects were observed. 
